secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-139402
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Soleno completes PWS trial enrollment, gets $10M; Q1 net loss $8.4M
-------------------------------------------------------------------

- Enrollment completed in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome; top-line data expected Q3 2023.
- Received $10M from closing of December 2022 securities purchase agreement with Nantahala, Abingworth, Vivo Capital; warrants for 22.6M shares issued.
- Cash and equivalents $7.9M at March 31, 2023; plus $10M received, expected to fund through top-line data.
- Net loss $8.4M ($0.88 per share) vs $5.7M ($1.07) in Q1 2022; R&D expenses $5.3M vs $4.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523139402/0001193125-23-139402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523139402/d421828d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-139402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer